Explore

Trendline Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Omeros Corporation to Release First Quarter 2026 Financial Results and Host Conference Call

Omeros Corporation to Release First Quarter 2026 Financial Results and Host Conference Call

Omeros Corporation to Release First Quarter 2026 Financial Results and Host Conference Call
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy
Trendline Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs
Trendline Trendline
enGene Faces Stock Plunge Amid Declining Response Rates in Bladder Cancer Therapy

enGene Faces Stock Plunge Amid Declining Response Rates in Bladder Cancer Therapy

enGene Faces Stock Plunge Amid Declining Response Rates in Bladder Cancer Therapy
Trendline Trendline
Coya Therapeutics Reports Financial Results and Advances ALS Treatment

Coya Therapeutics Reports Financial Results and Advances ALS Treatment

Coya Therapeutics Reports Financial Results and Advances ALS Treatment
Trendline Trendline
Almirall's European Dermatology Business Drives Q1 2026 Growth

Almirall's European Dermatology Business Drives Q1 2026 Growth

Almirall's European Dermatology Business Drives Q1 2026 Growth
Trendline Trendline
Arrowhead Pharmaceuticals Transitions to Fully Integrated Company Under CEO Christopher Anzalone

Arrowhead Pharmaceuticals Transitions to Fully Integrated Company Under CEO Christopher Anzalone

Arrowhead Pharmaceuticals Transitions to Fully Integrated Company Under CEO Christopher Anzalone
Trendline Trendline
Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges

Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges

Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges